PROJECT SUMMARY/ABSTRACT
This proposal is for a five-year research career development program, focused on understanding how
“neutropenic inflammation” activates the endothelium toward programmed cell death and the protective role of
necrotic cell death protein receptor interacting protein kinase-3 (RIPK3) in this inflammatory environment. The
candidate has been appointed Assistant Professor in the Department of Medicine at Weill Cornell Medicine. This
proposal is a natural extension of the candidate's previous research in high vascular injury ARDS populations
(Price DR, AJRCCM, 2021; ICM, 2021) and vascular cell death work in ARDS (Price DR, Am J Patho, 2023). It
outlines a plan for the candidate to achieve his goal of becoming an expert in vascular biology and acute lung
injury, extending the training of the candidate as identified here and reflected in the mentorship of Dr. Augustine
Choi and Dr. Shahin Rafii: 1. Define the role of neutropenic inflammation in mouse lung injury and human
organoid models, and 2. Determine a functional role for RIPK3 in inflammatory acute lung injury, and 3. Define
important necrotic cell death and vascular injury biomarkers in inflammatory ARDS. The proposed experiments
and the exciting training plan will impart the candidate with a unique combination of skills that will position him to
transition into a successful independent physician scientist studying vascular injury in ARDS.
The acute respiratory distress syndrome (ARDS) is a common, often fatal, inflammatory lung injury for which
there are limited therapeutic options. The role of vascular injury as a disease-modifying factor in ARDS
pathogenesis has been well established. In contrast, the functional significance of an aberrantly injured vascular
cell upregulating necrotic cell death proteins, including receptor interacting protein kinase 3 (RIPK3), remains
largely unexplored in ARDS investigations, representing a potential target for future ARDS therapeutics. In this
proposal, I leverage my recent work highlighting neutropenic ARDS as a high endothelial stress population to
propose studies that test how excessive “neutropenic inflammation” activates the endothelium toward
programmed cell death and the protective role of endothelial RIPK3 in this inflammatory environment. To do this,
I have developed a neutropenic lung injury model that activates the lung endothelium and promotes RIPK3
expression. In Aim1, we will define the role of neutropenic inflammation in mouse lung injury and human organoid
models. In Aim 2, we will determine a functional role for endothelial RIPK3 in acute lung injury using gene
targeted mice, specifically the endothelial cell-specific deletion of RIPK3 mice. And in Aim 3, we will characterize
dysregulated cell death and vascular permeability pathways in inflammatory ARDS by correlate circulating
necroptosis and vascular permeability proteins with mortality and clinical indices of acute lung injury. Collectively,
these studies will provide novel insight into pathways of neutropenic inflammation and endothelial RIPK3 in
regulating vascular injury in ARDS.